Clinical trials: Bladder
Overactive Bladder
Transvaginal Radiofrequency Ablation for Overactive Bladder
To assess the effectiveness of transvaginal radiofrequency oblation by the Morpheus device at varying depths of penetration for improving urge predominate and urinary incontinence symptoms in women with overactive bladder .
- Trial name
- NCT06458556
- Testing
- Treatment with Morpheus
- Where
- United States
- Volunteers
- 17 people, healthy volunteers welcome
- Sponsor
- InMode MD Ltd.
Locally Advanced or Metastatic Urothelial Carcinoma
A Study of the Safety and Efficacy of Various Combinations of Avelumab as Therapy in Locally Advanced or Metastatic Urothelial Carcinoma (JAVELIN Bladder Medley)
The purpose of this study is to assess the safety and efficacy of avelumab in combination with other anti-tumor agents as a maintenance treatment in participants with bladder cancer.
- Trial name
- NCT05327530
- Testing
- Avelumab, Sacituzumab Govitecan (SG), M6223
- Where
- 98 sites in United States, Australia and 10 more
- Volunteers
- 256 people
- Sponsor
- EMD Serono Research & Development Institute, Inc.
Bladder Cancer
A Study of Avelumab in Real-World Treatment for Patients With Advanced or Metastatic Urothelial Cancer
This ambispective (both retrospective and prospective) NIS will evaluate the effectiveness and safety of Avelumab as a maintenance therapy administered after completion of first-line platinum-based chemotherapy in patients with…
- Trial name
- NCT05568407
- Testing
- Avelumab
- Where
- 7 sites in Argentina, Brazil
- Volunteers
- 19 people
- Sponsor
- Pfizer
Overactive Bladder
Safety and Efficacy Study of Botulinum Toxin Type A for the Treatment of Neurogenic Overactive Bladder
The purpose of this study is to assess the safety and effectiveness of botulinum toxin type A in treating overactive bladder in spinal cord injury or multiple sclerosis patients
- Trial name
- NCT00461292
- Testing
- botulinum toxin Type A (200U), botulinum toxin Type A (300U)
- Where
- 12 sites in United States, Brazil and 10 more
- Volunteers
- 275 people
- Sponsor
- Allergan
Solid Tumor, Colon Carcinoma
PET-imaging of Two Vartumabs in Patients With Solid Tumors
VARTUTRACE is a first-in-human PET/CT molecular imaging study in patients with solid tumors. This study will investigate the biodistribution and pharmacology of two antibody fragments binding oncofetal Chondroitin Sulfate (CS).
- Conditions
- Solid Tumor, Colon Carcinoma, Rectal Carcinoma, Osteosarcoma
- Trial name
- VARTUTRACE (NCT06645808)
- Testing
- 89Zr-DFO-N-Suc-F8scFv, 89Zr-DFO-N-Suc-C9scFv, PET/CT scan
- Where
- Netherlands
- Volunteers
- 32 people
- Sponsor
- Var2 Pharmaceuticals
Urinary Tract Infections
Efficacy of BLASTX in Catheter Associated Bacteriuria Versus Standard of Care (SOC)
This is a 2-week, single-site, randomized study in adults requiring short-term (≤ 14 days) catheterization. Subjects will be randomized 1:1 to either the biofilm disrupting gel (BLASTX) or SOC (McKesson Jelly) lubricated…
- Trial name
- NCT03176394
- Testing
- BLASTX Gel, McKesson Jelly
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Next Science TM
Bladder Cancer
Phase Ib/II Study Assessing the Neo-adjuvant Combination Therapy of Vinflunine With Cisplatin Followed by Radical Cystectomy in Patients With Muscle-invasive Bladder Cancer (JaNEO)
Phase Ib/II study assessing the neo-adjuvant combination therapy of vinflunine with cisplatin followed by radical cystectomy in patients with muscle-invasive bladder cancer (JaNEO).
- Trial name
- JaNEO (NCT02845050)
- Testing
- Vinflunine, Cisplatin, Radical cystectomy
- Where
- 2 sites in Germany
- Sponsor
- Ligartis GmbH
Urothelial Carcinoma, Urothelial Carcinoma Bladder
9MW2821 + Toripalimab vs 9MW2821 for 1st Line Locally Advanced or Metastatic Urothelial Carcinoma
This study will compare the efficacy of 9MW2821+toripalimab versus 9MW2821 monotherapy in locally advanced or metastatic urothelial carcinoma patients who have not received any systemic treatment in the metastatic or advanced…
- Conditions
- Urothelial Carcinoma, Urothelial Carcinoma Bladder, Urothelial Carcinoma Recurrent, Urothelial Carcinoma of the Renal Pelvis and Ureter
- Trial name
- NCT06823427
- Testing
- 9MW2821, Toripalimab (JS001 )
- Where
- 2 sites in China
- Volunteers
- 60 people
- Sponsor
- Mabwell (Shanghai) Bioscience Co., Ltd.
Overactive Bladder
A Study to Evaluate the Effect of Mirabegron + Solifenacin in Overactive Bladder Patients
The purpose of this study was to evaluate the safety and efficacy of mirabegron as add-on therapy in patients with OAB treated with solifenacin.
- Trial name
- NCT01745094
- Testing
- mirabegron, solifenacin
- Where
- 5 sites in Japan
- Volunteers
- 223 people
- Sponsor
- Astellas Pharma Inc
Overactive Bladder
A Study Of Efficacy And Safety Of Fesoterodine In Vulnerable Elderly Subjects With Overactive Bladder
This study is designed to assess the efficacy and safety of a flexible dose regimen of fesoterodine on urgency urinary incontinence (UUI) episodes in vulnerable elderly subjects with overactive bladder (OAB).
- Trial name
- NCT00928070
- Testing
- Fesoterodine
- Where
- 125 sites in United States
- Volunteers
- 566 people
- Sponsor
- Pfizer
Detrusor Hyperreflexia
Safety and Efficacy Study of Transdermal Oxybutynin to Treat Overactive Bladder With a Neurological Condition
This study will evaluate the safety and effectiveness of an anticholinergic drug treatment administered by transdermal patch to treat overactive bladder in children who have a neurological condition (e.g.
- Trial name
- NCT00224016
- Testing
- Oxybutynin
- Where
- 23 sites in United States
- Volunteers
- 57 people
- Sponsor
- Watson Pharmaceuticals
Solid Tumors
Combination Therapy With NC-6004 and Gemcitabine in Advanced Solid Tumors or Non-Small Cell Lung, Biliary and Bladder Cancer
In the dose escalation phase (Part 1), this study will determine the dose-limiting toxicities (DLTs), the maximum tolerated dose (MTD) and recommended Phase 2 (RPII) dose of NC 6004 in combination with gemcitabine.
- Trial name
- NCT02240238
- Testing
- NC-6004, Gemcitabine
- Where
- 22 sites in United States, Bulgaria and 3 more
- Volunteers
- 119 people
- Sponsor
- NanoCarrier Co., Ltd.
Peripheral T Cell Lymphoma, Diffuse Large B Cell Lymphoma
A Study of STI-3031 (an Anti-PD-L1 Antibody) in Patients With Selected Relapsed/Refractory Malignancies
This study evaluates the efficacy, as measured by the objective response rate, of STI-3031, an anti-PD-L1 antibody, in previously treated patients with selected advanced lymphomas or biliary tract cancer.
- Conditions
- Peripheral T Cell Lymphoma, Diffuse Large B Cell Lymphoma, Biliary Tract Cancer, Extranodal NK T Cell Lymphoma, Nasal
- Trial name
- NCT03999658
- Testing
- STI-3031
- Sponsor
- Sorrento Therapeutics, Inc.
Overactive Bladder
Post Marketing Surveillance Study on Emselex After Launch in Germany
Data are obtained of Emselex in routine treatment of Overactive Bladder. The general objectives are to evaluate the product safety, compatibility, efficacy and patient acceptance.
- Trial name
- NCT00786448
- Testing
- Darifenacin, Emselex (BAY79-4998)
- Where
- Germany
- Volunteers
- 5,821 people
- Sponsor
- Bayer
Non Muscle Invasive Bladder Cancer, Urologic Cancer
A Study of Adjuvant Cretostimogene Grenadenorepvec for Treatment of Intermediate Risk NMIBC Following TURBT
This is a Phase 3, open-label, randomized trial designed to evaluate the RFS of TURBT followed by cretostimogene grenadenorepvec versus TURBT followed by surveillance for the treatment of participants with IR-NMIBC.
- Conditions
- Non Muscle Invasive Bladder Cancer, Urologic Cancer, Bladder Cancer, Urothelial Carcinoma
- Trial name
- NCT06111235
- Testing
- Cretostimogene Grenadenorepvec, n-dodecyl-B-D-maltoside
- Where
- 95 sites in United States, Canada
- Volunteers
- 367 people
- Sponsor
- CG Oncology, Inc.
Bladder Cancer, Neoplasms
Safety of Pre-TURBT Intravesical Instillation of Escalating Doses of TC-3 Gel and MMC in NMIBC Patients
A prospective, open label, modified 3+3 dose escalation study. This dose-escalation study is designed to carefully assess the safety of successive cohorts of patients (3 patients/cohort), each cohort treated with a fixed dose of…
- Conditions
- Bladder Cancer, Neoplasms, Urinary Bladder Diseases, Urologic Diseases
- Trial name
- NCT02307487
- Testing
- 120 mg MMC in 90ml gel, 140 mg MMC in 90ml gel, 160 mg MMC in 90ml gel
- Where
- 2 sites in Israel
- Volunteers
- 14 people
- Sponsor
- UroGen Pharma Ltd.
Non-muscle Invasive Bladder Cancer (NMIBC)
Phase 1/2 Study of ABI-009 in Nonmuscle Invasive Bladder Cancer
Purpose of this study is to determine appropriate dosing of ABI-009 and evaluate the safety and anti-tumor activity of ABI-009 in treatment of non-muscle invasive bladder cancer
- Trial name
- NCT02009332
- Testing
- ABI-009, Gemcitabine
- Where
- 2 sites in United States
- Volunteers
- 21 people
- Sponsor
- Aadi Bioscience, Inc.
Cystitis
Study to Evaluate the Efficacy and Safety of XC243 in Patients With Exacerbation of Chronic Cystitis
Multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of XC243 in patients with exacerbation of chronic cystitis.
- Trial name
- NCT06391164
- Testing
- XC243 25 mg, XC243 50 mg, XC243 75 mg
- Where
- 8 sites in Russia
- Volunteers
- 280 people
- Sponsor
- PHARMENTERPRISES LLC
Pressure Ulcers Stage III, Pressure Ulcer, Stage IV
Comparing Concomitant Use of ACell MicroMatrix® and ACell Cytal™ to Standard of Care in Stage 3 or 4 Pressure Injuries
The purpose of this study is to evaluate incidence of complete epithelialization in stage 3 \& 4 pressure ulcers using ACell products.
- Conditions
- Pressure Ulcers Stage III, Pressure Ulcer, Stage IV, Pressure Ulcer
- Trial name
- NCT03283787
- Testing
- MicroMatrix® and Cytal™ Wound Matrix 2-Layer, MicroMatrix® and Cytal™ Wound Matrix 2-Layer plus NPWT, Negative Pressure Wound Therapy
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- Integra LifeSciences Corporation
Non-muscle-invasive Bladder Cancer
T-Control® Safety for Cytostatics Management
The goal of this pilot clinical trial is to know if this study is feasable in terms of design, recruitment and interventions, as well as gather preliminary data to determine if the T-Control® catheter is safer than the…
- Trial name
- NCT06678633
- Testing
- T-Control® (experimental), Folysil® (control)
- Volunteers
- 16 people
- Sponsor
- Rethink Medical SL
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.